Article Text

PDF
Functional–morphological parameters, aqueous flare and cytokines in macular oedema with branch retinal vein occlusion after ranibizumab
  1. Hidetaka Noma1,
  2. Tatsuya Mimura2,
  3. Kanako Yasuda1,
  4. Masahiko Shimura1
  1. 1Department of Ophthalmology, Hachioji Medical Center, Tokyo Medical University, Tokyo, Japan
  2. 2Department of Ophthalmology, Medical Center East, Tokyo Women's Medical University, Tokyo, Japan
  1. Correspondence to Dr Hidetaka Noma, Department of Ophthalmology, Hachioji Medical Center, Tokyo Medical University, 1163, Tatemachi, Hachioji, Tokyo 193-0998, Japan; noma-hide{at}umin.ac.jp

Abstract

Background/aims Correlations among functional–morphological parameters, the aqueous flare value (an indicator of inflammation) and aqueous humour levels of cytokines/inflammatory factors were investigated in patients with branch retinal vein occlusion (BRVO) and macular oedema who received intravitreal ranibizumab injection (IRI) and were followed for 6 months.

Methods Aqueous humour levels of 11 cytokines or growth inflammatory/factors were measured in 45 patients with BRVO and macular oedema who received IRI. Patients with recurrent macular oedema were given further IRI as needed. Aqueous humour levels of vascular endothelial growth factor (VEGF), soluble VEGF receptor (sVEGFR) and other cytokines/inflammatory factors were measured by the suspension array method. Aqueous flare values were measured with a laser flare metre and macular oedema was examined by optical coherence tomography.

Results There were significant correlations between the aqueous flare and the aqueous levels of sVEGFR-1, placental growth factor, monocyte chemoattractant protein 1, soluble intercellular adhesion molecule-1, interleukin (IL)-6 and IL-8. There were also significant correlations between the change of the aqueous flare and improvement of central macular thickness after 1 month, after 6 months and at the 1st recurrence. Furthermore, a significant correlation was noted between the change of the aqueous flare and improvement of best-corrected visual acuity at 6 months after IRI, but not at 1 month or at the 1st recurrence.

Conclusions These findings suggest that the aqueous flare is associated with inflammatory factors/cytokines, and that the change of the aqueous flare value may influence the long-term prognosis in patients with BRVO receiving IRI therapy for macular oedema.

  • Treatment Medical
  • Retina
  • Macula
  • Inflammation
  • Aqueous humour

Statistics from Altmetric.com

Footnotes

  • Contributors HN and MS were involved in the design and conduct of the study. Collection and management of the data were done by HN and KY, while analysis and interpretation of the data were performed by HN, TM and MS. Preparation of the first draft of the manuscript was done by HN, and review and approval of the manuscript was performed by TM, KY and MS.

  • Funding This work was partially supported by Novartis Pharma K.K.

  • Competing interests Novartis Pharma K.K. and Novartis AG were offered an opportunity to comment on the research plan and this manuscript during the review process, but they had no role in the design or conduct of this research.

  • Ethics approval This study was conducted at the Department of Ophthalmology of Tokyo Medical University's Hachioji Medical Center.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • At a glance
    Keith Barton James Chodosh Jost Jonas